A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma.

ABSTRACT:

Background

Mycetoma caused by Madurella mycetomatis (eumycetoma) is a neglected tropical disease that forms tumorous lesions in the subcutaneous tissue. The current standard treatment for eumycetoma consists of antifungal treatment combined with surgery, with limited success rates. Due to lack of investment, there are currently no large drug discovery programmes for mycetoma. Repurposing screening can therefore offer an effective and economical way to identify drugs that can be effective in eumycetoma treatment. Therefore, in this study we determined the in vitro activity and in vivo efficacy of 5631 compounds present in the Oncode Drug Repurposing library.

Methods

In total, 5631 drugs from the Oncode Drug Repurposing library were screened for in vitro activity against M. my

SUBMITTER: Ma J 

PROVIDER: S-EPMC12670160 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature